Laurion reports 6.06% stake in Immunic

Rhea-AI Filing Summary

Laurion Capital Management LP and related reporting persons disclosed that, as of June 30, 2026, they may be deemed to beneficially own 839,526 shares of Immunic, Inc. common stock, including 229,200 shares issuable upon exercise of warrants, representing 6.06% of the company’s common stock.

The stake is held through Laurion funds, with Laurion Capital, Benjamin Alexander Smith, and Janaka Sheehan Maduraperuma each reporting shared voting and dispositive power over the 839,526 shares and no sole voting or dispositive power. Laurion Capital Master Fund Ltd. has rights to dividends or sale proceeds on more than 5% of the shares.

Key Figures

Beneficial ownership: 839,526 shares Ownership percentage: 6.06% Common shares held: 610,326 shares +2 more

5 metrics

Beneficial ownership 839,526 shares Shares of Immunic common stock Laurion reporting persons may be deemed to beneficially own as of June 30, 2026

Ownership percentage 6.06% Percentage of Immunic common stock represented by Laurion’s reported holdings

Common shares held 610,326 shares Portion of Laurion’s beneficial ownership held as outstanding Immunic common stock

Warrant shares 229,200 shares Immunic common shares issuable upon exercise of warrants held by Laurion funds

Shares outstanding baseline 13,621,526 shares Immunic common shares issued and outstanding as of March 31, 2026, used in ownership calculation

Key Terms

beneficially own, shared voting power, dispositive power, CUSIP Number, +1 more

5 terms

beneficially own financial

"may be deemed to beneficially own an aggregate of 839,526 shares of common stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared voting power financial

"Shared Voting Power 839,526.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"Shared Dispositive Power 839,526.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

CUSIP Number financial

"CUSIP Number(s): 4525EP200"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

investment adviser financial

"the investment adviser to certain funds and accounts (the "Laurion Funds")"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Immunic, Inc. (IMUX) does Laurion Capital report?

Laurion Capital and related reporting persons may be deemed to beneficially own 839,526 shares of Immunic common stock, including warrant shares, representing 6.06% of the outstanding common stock as of June 30, 2026, based on the issuer’s reported share count.

How is Laurion Capital’s 839,526-share position in IMUX structured?

The reported 839,526 shares consist of 610,326 common shares and 229,200 shares of common stock issuable upon exercise of warrants. These securities are held by Laurion funds for which Laurion Capital acts as investment adviser.

What percentage of Immunic (IMUX) does Laurion Capital’s position represent?

Laurion Capital’s reported holdings represent 6.06% of Immunic’s common stock. This percentage is calculated using 13,621,526 shares outstanding as of March 31, 2026, plus 229,200 warrant shares that the Laurion funds may acquire.

Who has voting and dispositive power over Laurion Capital’s IMUX shares?

Laurion Capital, Benjamin Alexander Smith, and Janaka Sheehan Maduraperuma each report 0 shares with sole power and 839,526 shares with shared power to vote and dispose. The shares are held by Laurion-managed funds, not directly by the individuals.

Which Laurion fund holds more than 5% of Immunic (IMUX) shares?

Laurion Capital Master Fund Ltd., a Laurion fund, has the right to receive or direct the receipt of dividends or sale proceeds from more than 5% of Immunic’s common stock, reflecting its significant economic interest in the position.

What share count did Laurion use to calculate its 6.06% IMUX ownership?

The 6.06% ownership figure is based on 13,621,526 Immunic shares reported as issued and outstanding as of March 31, 2026, plus 229,200 shares of common stock that the Laurion funds may acquire upon exercising warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 05:49 PM Accepted by SEC EDGAR 08/04/2026 - 05:48 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

IMMUNIC, INC.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

4525EP200

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 4525EP200

1

Names of Reporting Persons

Laurion Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 839,526.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 839,526.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

839,526.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.06 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 4525EP200

1

Names of Reporting Persons

Benjamin Alexander Smith

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 839,526.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 839,526.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

839,526.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.06 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 4525EP200

1

Names of Reporting Persons

Janaka Sheehan Maduraperuma

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 839,526.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 839,526.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

839,526.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.06 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNIC, INC.
(b)	Address of issuer's principal executive offices: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK, UNITED STATES 10036
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Laurion Capital Management LP ("Laurion Capital"), a Delaware limited partnership, and the investment adviser to certain funds and accounts (the "Laurion Funds"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Laurion Funds; (ii) Mr. Benjamin Alexander Smith ("Mr. Smith"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds. (iii) Mr. Janaka Sheehan Maduraperuma ("Mr. Maduraperuma"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 360 Madison Avenue, Suite 1900, New York, NY 10017.
(c)	Citizenship: Laurion Capital is a Delaware limited partnership. Mr. Smith is a citizen of the United States. Mr. Maduraperuma is a citizen of the United Kingdom.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP Number(s): 4525EP200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2026, the Reporting Persons may be deemed to beneficially own an aggregate of 839,526 shares of common stock, par value $0.0001 per share (the "Common Stock") of Immunic, Inc. (the "Issuer"), consisting of (i) 610,326 shares of Common Stock; and (ii) 229,200 shares of Common Stock issuable upon the exercise of warrants issued by the Issuer. The ownership percentages reported herein are based on 13,621,526 shares of Common Stock reported as issued and outstanding as of March 31, 2026 in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2026, plus 229,200 shares of Common Stock which the Laurion Funds may acquire upon the exercise of the warrants.
(b)	Percent of class: 6.06 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Laurion Capital Management LP - 0 Benjamin Alexander Smith - 0 Janaka Sheehan Maduraperuma - 0
	(ii) Shared power to vote or to direct the vote: Laurion Capital Management LP - 839,526 Benjamin Alexander Smith - 839,526 Janaka Sheehan Maduraperuma - 839,526
	(iii) Sole power to dispose or to direct the disposition of: Laurion Capital Management LP - 0 Benjamin Alexander Smith - 0 Janaka Sheehan Maduraperuma - 0
	(iv) Shared power to dispose or to direct the disposition of: Laurion Capital Management LP - 839,526 Benjamin Alexander Smith - 839,526 Janaka Sheehan Maduraperuma - 839,526
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2. The Laurion Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Laurion Capital Master Fund Ltd., a Laurion Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Item 2(a) and Item 3
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Laurion Capital Management LP

Signature:	Jason Riesel
Name/Title:	Jason Riesel. General Counsel & CCO
Date:	08/04/2026

Benjamin Alexander Smith

Signature:	Benjamin Alexander Smith
Name/Title:	Benjamin Alexander Smith
Date:	08/04/2026

Janaka Sheehan Maduraperuma

Signature:	Janaka Sheehan Maduraperuma
Name/Title:	Janaka Sheehan Maduraperuma
Date:	08/04/2026